{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:06:52Z","timestamp":1787314012299,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The adherence pattern of antiepileptic drugs (AEDs) among patients with epilepsy is relatively lower in the United States and different European countries. However, adherence and cost analysis of AEDs in Asian countries have not been thoroughly studied. Therefore, the present study aimed to analyze the cost and adherence of AEDs and its associated factors in patients followed in Pakistan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from prescriptions collected from patients with epilepsy who have visited the Outpatient Department (OPD) of different tertiary care hospitals at the cosmopolitan city of Karachi, Pakistan from December 2015 to November 2019. The mean follow-up period for each participant was about 22 months. Pairwise comparisons from Cox regression\/hazard ratios were used to assess the predictors of adherence. Direct costs of AEDs were calculated and presented as the annual cost of drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 11,490 patients were included in this study, 51.2\u2009% were male and 48.8\u2009% were female with a mean age of 45.2\u2009\u00b1\u200915.8 y. Levetiracetam was found as the most prescribing AED in all study participants (32.9\u2009%). Of them, 49.1\u2009% of patients continued their initial recommended treatment. However, 31.3\u2009% of patients have discontinued the therapy, while, 19.6\u2009% were switched to other AED. Adherence with initial treatment was more profound in male (57.4\u2009%) patients, compared to female with a mean age of 44.2\u00a0years. Lamotrigine users (60.6\u2009%) showed a higher tendency to retain on initially prescribed drugs. The total cost of epilepsy treatment in the entire study cohort was 153280.5 PKR ($941.9). By applying the Cox regression analysis, it can be observed that the patients with increasing age (OR, 2.04), migraine (OR, 2.21), psychiatric disorders (OR, 4.28), other comorbidities (OR, 1.52) and users of other than top five prescribing AEDs (2.35) were at higher risk of treatment discontinuation. However, levetiracetam (OR, 0.69), valproic acid (OR, 0.52), carbamazepine (OR, 0.81), lamotrigine (OR, 0.80) or lacosamide (OR, 0.65) users have more chances to continue their initial therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Similar to western countries, the majority of patients with epilepsy exhibited low adherence with AEDs. Various associated factors for improving adherence were identified in this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-021-06085-0","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T16:02:52Z","timestamp":1611072172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Analysis of treatment adherence and cost among patients with epilepsy: a four\u2010year retrospective cohort study in Pakistan"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3220-8418","authenticated-orcid":false,"given":"Muhammad Arif","family":"Asghar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahad Abdul","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Liaquat","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousra","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Asif","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"issue":"10172","key":"6085_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","volume":"393","author":"RD Thijs","year":"2019","unstructured":"Thijs RD, Surges R, O\u2019Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689\u2013701.","journal-title":"Lancet"},{"issue":"3\u20134","key":"6085_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000493484","volume":"51","author":"E Beghi","year":"2018","unstructured":"Beghi E, Giussani G. Aging and the epidemiology of epilepsy. Neuroepidemiol. 2018;51(3\u20134):216\u201323.","journal-title":"Neuroepidemiol"},{"issue":"7","key":"6085_CR3","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/epi.12605","volume":"55","author":"GS Bell","year":"2014","unstructured":"Bell GS, Neligan A, Sander JW. An unknown quantity - the worldwide prevalence of epilepsy. Epilepsia. 2014;55(7):958\u201362.","journal-title":"Epilepsia"},{"key":"6085_CR4","unstructured":"World Health Organization. Epilepsy fact sheet. 2017. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/epilepsy."},{"issue":"12","key":"6085_CR5","first-page":"594","volume":"53","author":"I Khatri","year":"2003","unstructured":"Khatri I, Iannaccone S, Ilyas M, Abdullah M, Saleem S. Epidemiology of epilepsy in Pakistan: review of literature. J Pak Med Assoc. 2003;53(12):594\u20136.","journal-title":"J Pak Med Assoc"},{"issue":"3","key":"6085_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.yebeh.2012.08.027","volume":"25","author":"E Faught","year":"2012","unstructured":"Faught E. Adherence to antiepilepsy drug therapy. Epilepsy Behav. 2012;25(3):297\u2013302.","journal-title":"Epilepsy Behav"},{"key":"6085_CR7","first-page":"111","volume":"1","author":"R Mattson","year":"1988","unstructured":"Mattson R, Cramer J, Collins J. Aspects of compliance: taking drugs and keeping clinic appointments. Epilepsy Res Suppl. 1988;1:111\u20137.","journal-title":"Epilepsy Res Suppl"},{"issue":"774","key":"6085_CR8","first-page":"150","volume":"98","author":"L Stanaway","year":"1985","unstructured":"Stanaway L, Lambie D, Johnson R. Non-compliance with anticonvulsant therapy as a cause of seizures. N Z Med J. 1985;98(774):150\u20132.","journal-title":"N Z Med J"},{"issue":"5","key":"6085_CR9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/WNL.0000000000002791","volume":"87","author":"S Gollwitzer","year":"2016","unstructured":"Gollwitzer S, Kostev K, Hagge M, Lang J, Graf W, Hamer HM. Nonadherence to antiepileptic drugs in Germany: a retrospective, population-based study. Neurol. 2016;87(5):466\u201372.","journal-title":"Neurol"},{"issue":"1","key":"6085_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/jpepsy\/jsu010","volume":"40","author":"BS Aylward","year":"2015","unstructured":"Aylward BS, Rausch JR, Modi AC. An examination of 1-year adherence and persistence rates to antiepileptic medication in children with newly diagnosed epilepsy. J Pediatr Psychol. 2015;40(1):66\u201374.","journal-title":"J Pediatr Psychol"},{"issue":"4","key":"6085_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1684\/epd.2016.0871","volume":"18","author":"YK Lee","year":"2016","unstructured":"Lee YK, Ah YM, Choi YJ, Cho YS, Kim KJ, Lee JY. Antiepileptic drug adherence and persistence in children with epilepsy attending a large tertiary care children\u2019s hospital. Epileptic Dis. 2016;18(4):408\u201317.","journal-title":"Epileptic Dis"},{"issue":"2","key":"6085_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.yebeh.2008.12.006","volume":"14","author":"R Manjunath","year":"2009","unstructured":"Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav. 2009;14(2):372\u20138.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"6085_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.31925\/farmacia.2019.6.23","volume":"67","author":"MA Asghar","year":"2019","unstructured":"Asghar MA, Rehman AA, Raza ML, Mumtaz N, Asghar MA, Shafiq Y, et al. Prescription pattern of antiepileptic drugs in southern Pakistan: A retrospective cohort study in tertiary care centers. Farmacia. 2019;67(6):1091\u20138.","journal-title":"Farmacia"},{"issue":"3","key":"6085_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.phclin.2017.06.002","volume":"52","author":"MA Asghar","year":"2017","unstructured":"Asghar MA, Mumtaz N, Niaz S, Zaheer K, Raza ML. Prescribing behavior of practitioners in public and private hospitals in Pakistan evaluated using the World Health Organization (WHO) indicators: A comparative approach. Le Pharmacien Hospitalier et Clinicien. 2017;52(3):299\u2013305.","journal-title":"Le Pharmacien Hospitalier et Clinicien"},{"issue":"5","key":"6085_CR15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1528-1167.2005.52704.x","volume":"46","author":"D Chisholm","year":"2005","unstructured":"Chisholm D. Cost-effectiveness of first\u2010line antiepileptic drug treatments in the developing world: a population\u2010level analysis. Epilepsia. 2005;46(5):751\u20139.","journal-title":"Epilepsia"},{"issue":"35","key":"6085_CR16","doi-asserted-by":"publisher","first-page":"e4481","DOI":"10.1097\/MD.0000000000004481","volume":"95","author":"EC Lai","year":"2016","unstructured":"Lai EC, Hsieh CY, Su CC, Yang YK, Huang CW, Lin SJ, et al. Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study. Med. 2016;95(35):e4481.","journal-title":"Med"},{"key":"6085_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.seizure.2017.09.008","volume":"52","author":"MIA Rahim","year":"2017","unstructured":"Rahim MIA, Thomas RH. Gamification of medication adherence in epilepsy. Seizure. 2017;52:11\u20134.","journal-title":"Seizure"},{"issue":"8","key":"6085_CR18","doi-asserted-by":"publisher","first-page":"180850","DOI":"10.1098\/rsos.180850","volume":"6","author":"A Javor","year":"2019","unstructured":"Javor A, Ciumas C, Ibarrola D, Ryvlin P, Rheims S. Social cognition, behaviour and therapy adherence in frontal lobe epilepsy: a study combining neuroeconomic and neuropsychological methods. Royal Soc Open Sci. 2019;6(8):180850.","journal-title":"Royal Soc Open Sci"},{"key":"6085_CR19","first-page":"12","volume":"45","author":"YL Niriayo","year":"2019","unstructured":"Niriayo YL, Mamo A, Gidey K, Demoz GT. Medication Belief and Adherence among Patients with Epilepsy. Behav Neurol. 2019;45:12\u20137.","journal-title":"Behav Neurol"},{"key":"6085_CR20","unstructured":"Dean A, Sullivan K, Soe M. OpenEpi. Open source epidemiologic statistics for public health (Version 2.3. 1)[Software] 2006."},{"key":"6085_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2016.02.001","volume":"122","author":"E Brodtkorb","year":"2006","unstructured":"Brodtkorb E, Samsonsen C, Sund JK, Br\u00e5then G, Helde G, Reimers A. Treatment non-adherence in pseudo-refractory epilepsy. Epilepsy Res. 2006;122:1\u20136.","journal-title":"Epilepsy Res"},{"issue":"10231","key":"6085_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","volume":"395","author":"JM Chamberlain","year":"2020","unstructured":"Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020;395(10231):1217\u201324.","journal-title":"Lancet"},{"issue":"1","key":"6085_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/JNN.0000000000000259","volume":"49","author":"A Collins-Yoder","year":"2017","unstructured":"Collins-Yoder A, Lowell J. Valproic acid: special considerations and targeted monitoring. J Neurosci Nurs. 2017;49(1):56\u201361.","journal-title":"J Neurosci Nurs"},{"key":"6085_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.yebeh.2018.07.023","volume":"98","author":"JA Salpekar","year":"2019","unstructured":"Salpekar JA, Mula M. Common psychiatric comorbidities in epilepsy: how big of a problem is it? Epilepsy Behav. 2019;98:293\u20137.","journal-title":"Epilepsy Behav"},{"key":"6085_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/B978-0-12-814877-8.00002-7","volume":"56","author":"C-S Kwon","year":"2019","unstructured":"Kwon C-S, Begley CE, Jett\u00e9 N. Costs of epilepsy: The impact of comorbidities. The Comorbidities of Epilepsy: Elsevier. 2019;56:13\u201325.","journal-title":"The Comorbidities of Epilepsy: Elsevier"},{"key":"6085_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.yebeh.2019.05.038","volume":"97","author":"G Zaccara","year":"2019","unstructured":"Zaccara G, Lattanzi S. Comorbidity between epilepsy and cardiac arrhythmias: Implication for treatment. Epilepsy Behav. 2019;97:304\u201312.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"6085_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","volume":"15","author":"MR Keezer","year":"2016","unstructured":"Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016;15(1):106\u201315.","journal-title":"Lancet Neurol"},{"issue":"4","key":"6085_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11940-019-0558-1","volume":"21","author":"SK Parikh","year":"2019","unstructured":"Parikh SK, Silberstein SD. Current status of antiepileptic drugs as preventive migraine therapy. Curr Treat Options Neurol. 2019;21(4):16\u201323.","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"6085_CR29","doi-asserted-by":"publisher","first-page":"s161","DOI":"10.1007\/s10072-004-0278-4","volume":"25","author":"F Frediani","year":"2004","unstructured":"Frediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci. 2004;25(3):s161\u2013s166.","journal-title":"Neurol Sci"},{"issue":"9","key":"6085_CR30","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/ene.13069","volume":"23","author":"B Berghuis","year":"2016","unstructured":"Berghuis B, de Haan GJ, van den Broek M, Sander J, Lindhout D, Koeleman B. Epidemiology, pathophysiology and putative genetic basis of carbamazepine-and oxcarbazepine\u2010induced hyponatremia. Eur J Neurol. 2016;23(9):1393\u20139.","journal-title":"Eur J Neurol"},{"issue":"4","key":"6085_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.yebeh.2012.02.002","volume":"23","author":"RED Bautista","year":"2012","unstructured":"Bautista RED, Rundle-Gonzalez V. Effects of antiepileptic drug characteristics on medication adherence. Epilepsy Behav. 2012;23(4):437\u201341.","journal-title":"Epilepsy Behav"},{"issue":"20","key":"6085_CR32","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","volume":"71","author":"E Faught","year":"2008","unstructured":"Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurol. 2008;71(20):1572\u20138.","journal-title":"Neurol"},{"issue":"3","key":"6085_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1528-1167.2007.01414.x","volume":"49","author":"KL Davis","year":"2008","unstructured":"Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008;49(3):446\u201354.","journal-title":"Epilepsia"},{"issue":"16","key":"6085_CR34","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jama.2011.506","volume":"305","author":"AC Modi","year":"2011","unstructured":"Modi AC, Rausch JR, Glauser TA. Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy. JAMA. 2011;305(16):1669\u201376.","journal-title":"JAMA"},{"issue":"1","key":"6085_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jsps.2014.05.003","volume":"23","author":"WM Gabr","year":"2015","unstructured":"Gabr WM, Shams ME. Adherence to medication among outpatient adolescents with epilepsy. Saudi Pharm J. 2015;23(1):33\u201340.","journal-title":"Saudi Pharm J"},{"issue":"10","key":"6085_CR36","first-page":"34","volume":"82","author":"V Divino","year":"2014","unstructured":"Divino V, Petrilla A, Hallinan S, Bollu V, Velez F, Ettinger A, et al. Real-world persistence and treatment failure associated with first line use of antiepileptic drug treatment in a large US managed care population. Neurol. 2014;82(10):34\u20138.","journal-title":"Neurol"},{"issue":"3","key":"6085_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1684\/epd.2013.0588","volume":"15","author":"J Liu","year":"2013","unstructured":"Liu J, Liu Z, Ding H, Yang X. Adherence to treatment and influencing factors in a sample of Chinese epilepsy patients. Epileptic Dis. 2013;15(3):289\u201394.","journal-title":"Epileptic Dis"},{"issue":"12","key":"6085_CR38","first-page":"398","volume":"19","author":"S Jung","year":"2019","unstructured":"Jung S, Tak SH. Medication Non-adherence and Related Factors of Older Adults Who Use Polypharmacy Based on Medication Adherence Model. J Korea Contents Assoc. 2019;19(12):398\u2013406.","journal-title":"J Korea Contents Assoc"},{"key":"6085_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.yebeh.2017.06.008","volume":"73","author":"L Jacob","year":"2017","unstructured":"Jacob L, Hamer HM, Kostev K. Persistence with antiepileptic drugs in epilepsy patients treated in neurological practices in Germany. Epilepsy Behav. 2017;73:204\u20137.","journal-title":"Epilepsy Behav"},{"key":"6085_CR40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.seizure.2020.01.004","volume":"76","author":"K Kurvits","year":"2020","unstructured":"Kurvits K, Laius O, Uusk\u00fcla M, Haldre S, Rakitin A. Valproic acid prescription trends among females of childbearing age in Estonia: A 14-year nationwide prescription database study. Seizure. 2020;76:28\u201331.","journal-title":"Seizure"},{"issue":"2","key":"6085_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1059-1311(97)80060-X","volume":"6","author":"D Buck","year":"1997","unstructured":"Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic drug regimes. Seizure. 1997;6(2):87\u201393.","journal-title":"Seizure"},{"issue":"2","key":"6085_CR42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","volume":"32","author":"T Tomson","year":"2019","unstructured":"Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32(2):246\u201352.","journal-title":"Curr Opin Neurol"},{"issue":"9566","key":"6085_CR43","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000\u201315.","journal-title":"Lancet"},{"issue":"3","key":"6085_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1528-1167.2008.01794.x","volume":"50","author":"RE Faught","year":"2009","unstructured":"Faught RE, Weiner JR, Gu\u00e9rin A, Cunnington MC, Duh MS. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia. 2009;50(3):501\u20139.","journal-title":"Epilepsia"},{"issue":"4","key":"6085_CR45","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.18203\/2319-2003.ijbcp20162485","volume":"5","author":"AK Shukla","year":"2016","unstructured":"Shukla AK, Mehani R. Cost analysis of antiepileptic drugs available in India. Int J Basic Clin Pharmacol. 2016;5(4):1636\u201340.","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"10","key":"6085_CR46","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1111\/head.12233","volume":"53","author":"E Loder","year":"2013","unstructured":"Loder E, Weizenbaum E, Frishberg B, Silberstein S, Force AH. Choosing Wisely in Headache Medicine: The American Headache Society\u2019s list of five things physicians and patients should question. headache. J Head Face Pain. 2013;53(10):1651\u20139.","journal-title":"J Head Face Pain"},{"issue":"2","key":"6085_CR47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.18553\/jmcp.2005.11.2.137","volume":"11","author":"LR Etemad","year":"2005","unstructured":"Etemad LR, Yang W, Globe D, Barlev A, Johnson KA. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Managed Care Pharm. 2005;11(2):137\u201344.","journal-title":"J Managed Care Pharm"},{"issue":"7","key":"6085_CR48","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/head.12404","volume":"54","author":"AJ Messali","year":"2014","unstructured":"Messali AJ, Yang M, Gillard P, Tsai K, Tepper SJ, Bloudek LM, et al. Treatment persistence and switching in triptan users: a systematic literature review. Headache: J Head Face Pain. 2014;54(7):1120\u201330.","journal-title":"Headache: J Head Face Pain"},{"issue":"5","key":"6085_CR49","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40258-019-00487-2","volume":"17","author":"LM Willems","year":"2019","unstructured":"Willems LM, Hamer HM, Knake S, Rosenow F, Reese JP, Strzelczyk A. \u201cGeneral Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data. Appl Health Econ Health Policy. 2019;17(5):707\u201322.","journal-title":"Appl Health Econ Health Policy"},{"key":"6085_CR50","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.yebeh.2018.03.025","volume":"83","author":"LM Willems","year":"2018","unstructured":"Willems LM, Richter S, Watermann N, Bauer S, Klein KM, Reese JP, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013\u2014a ten-year overview. Epilepsy Behav. 2018;83:28\u201335.","journal-title":"Epilepsy Behav"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-06085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-021-06085-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-06085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T16:10:01Z","timestamp":1611072601000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-021-06085-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6085"],"URL":"https:\/\/doi.org\/10.1186\/s12913-021-06085-0","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"22 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethical board of Ziauddin Hospital, Karachi, Pakistan has approved this cohort study with reference to our previous study (Ref # 28\/02\/KK\/ZHC). All participants gave their written informed consent to participate in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}